CYTX : Analysis & Opinions
Cytori Therapeutics continues to bolster its IP portfolio after receiving new drug patents in the US and Europe.
Cytori Therapeutics secured orphan drug status for its ECCS-50 drug to treat scleroderma.
Cytori posted a 3Q loss and revenue below analyst estimates.
The renewed contract option indicates on-track progress of Cytori Cell Therapy, along with increased valuations.